You are here: Home Published Research Primary vaccination with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in infants in Mali and Nigeria: a randomized controlled trial.

Alassane Dicko, Olumuyiwa O Odusanya, Abdoulbaki I Diallo, Gaoussou Santara, Amadou Barry, Amagana Dolo, Aminata Diallo, Yetunde A Kuyinu, Omolara A Kehinde, Nancy Fran├žois, Dorota Borys, Juan P Yarzabal, Marta Moreira, and Lode Schuerman (2011)

Primary vaccination with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in infants in Mali and Nigeria: a randomized controlled trial.

BMC public health, 11:882.

Pneumonia is still the leading cause of death among children in Africa, and pneumococcal serotypes 1 and 5 are frequently isolated from African children with invasive pneumococcal disease below the age of 5 years. The immunogenicity, safety and reactogenicity of 3-dose primary vaccination with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) were evaluated in infants in Mali and Nigeria.

Africa South of the Sahara, Bacterial Proteins, Carrier Proteins, Female, Haemophilus Infections, Haemophilus influenzae, Humans, Immunoglobulin D, Infant, Lipoproteins, Male, Mali, Nigeria, Pneumococcal Vaccines, Primary Prevention
Africa South of the Sahara, Bacterial Proteins, Carrier Proteins, Female, Haemophilus Infections, Haemophilus influenzae, Humans, Immunoglobulin D, Infant, Lipoproteins, Male, Mali, Nigeria, Pneumococcal Vaccines, Primary Prevention
 
Document Actions